Showing 1,661 - 1,680 results of 18,267 for search 'significant ((((teer decrease) OR (a decrease))) OR (mean decrease))', query time: 0.40s Refine Results
  1. 1661
  2. 1662
  3. 1663
  4. 1664
  5. 1665
  6. 1666
  7. 1667
  8. 1668

    Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

    Published 2024
    “…The analysis found a significant association across all subjects for Shannon diversity with decreasing diversity in the lead up to the next treatment (lmer model, beta = -0.018, <i>p</i> = 0.036) and no association for observed diversity (<i>p</i>>0.1). …”
  9. 1669
  10. 1670
  11. 1671
  12. 1672
  13. 1673
  14. 1674
  15. 1675
  16. 1676
  17. 1677
  18. 1678

    Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

    Published 2025
    “…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”
  19. 1679

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 1680

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”